Myocarditis overview: Difference between revisions

Jump to navigation Jump to search
Line 72: Line 72:
*[[Pericardial effusion]]
*[[Pericardial effusion]]
*Functional regurgitation through the AV valves may be noted due to [[ventricular dilation]].
*Functional regurgitation through the AV valves may be noted due to [[ventricular dilation]].
In general, [[left ventricular function]] improves in fulminant myocarditis over a course of approximately 6 months<ref name="pmid10898439">{{cite journal| author=Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL et al.| title=Echocardiographic findings in fulminant and acute myocarditis. | journal=J Am Coll Cardiol | year= 2000 | volume= 36 | issue= 1 | pages= 227-32 | pmid=10898439 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10898439  }} </ref>.
 
In general, [[left ventricular function]] improves in fulminant myocarditis over a course of approximately 6 months<ref name="pmid10898439">{{cite journal| author=Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL et al.| title=Echocardiographic findings in fulminant and acute myocarditis. | journal=J Am Coll Cardiol | year= 2000 | volume= 36 | issue= 1 | pages= 227-32 | pmid=10898439 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10898439  }} </ref>.


===Endomyocardial Biopsy===
===Endomyocardial Biopsy===

Revision as of 18:50, 11 September 2011

Myocarditis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Adrenergic Myocarditis
Giant Cell Myocarditis

Causes

Differentiating Myocarditis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Myocarditis overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Google Images

American Roentgen Ray Society Images of Myocarditis overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Myocarditis overview

CDC on Myocarditis overview

Myocarditis overview in the news

Blogs on Myocarditis overview

Directions to Hospitals Treating Type page name here

Risk calculators and risk factors for Myocarditis overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Varun Kumar, M.B.B.S.

Overview

Myocarditis is inflammation of the myocardium. It may present with chest pain, ST segment elevation, elevated biomarkers of myonecrosis, heart failure, and / or sudden death.

Pathophysiology

During either an infection or a hypersensitivity reaction, the inflammatory response may cause myonecrosis either directly or indirectly as part of an autoimmune reaction. Myocarditis is a continuum of three phases of the disease processes with each one evolving into the next[1]:

Phase I: Viral Infection and Replication

Viruses such as coxsackie and enterovirus, get internalized in peripheral tissues and activate the immune system. A few of these viral genomes attach to the immunologic cells which circulate throughout the body and lodge in other organs such as the heart where they further replicate and cause localized tissue destruction.

Phase II: Autoimmune Injury

After the host immune system eliminates the viral genomes from the body, the immune system may remains activated in patients who develop myocarditis. This leads to the development of an autoimmune reaction where T-cells and cytokines target the host tissue such as the myocardium which causes further myocyte damage.

Phase III: Dilated Cardiomyopathy

Cytokines, which are produced in reaction to infection and cell death, are a leading cause of dilated cardiomyopathy. Matrix metalloproteinases, such as gelatinase, collagenases, and elastases may also be activated by cytokines during the autoimmune phase[2][3]. Protease produced by coxsackie virus can also modify the sarcoglycan complex in myocytes[4] leading to ventricular dilation.

Eosinophilic and hypersensitive myocarditis may occur secondary to parasitic infections, drug hypersensitivity or hypereosinophilic syndrome. Eosinophilic infiltration in myocardium lead to release of eosinophilic proteins which increase cellular membrane permeability which in turn leads to cell death[5][6].

Epidemiology and Demographics

In developed countries, myocarditis is generally due to viral infections such as coxsackie B, enterovirus,adenovirus, parvovirus B19, hepatitis C, and herpes virus 6. In developing countries, myocarditis is generally due to HIV and rheumatic heart disease. In routine autopsies, 1-9% of all patients had evidence of myocardial inflammation. In young adults, up to 20% of all cases of sudden death are due to myocarditis. There is a male predominance.

Natural History, Complications & Prognosis

Myocarditis is usually self limiting and is associated with a good prognosis especially if it is secondary to a viral infection. Patients rarely develop cardiac failure, pulmonary edema, arrhythmias or cardiogenic shock. In some instances, myocarditis may be associated with sudden death. Patients with fulminant myocarditis have a good long term prognosis if they survive the acute phase of the disease [7] . The prognosis of fulminant myocarditis is better than that of either acute myocarditis or giant cell myocarditis.

The presence of left bundle branch block, q waves, AV block, syncope and a left ventricular ejection fraction < 40% are associated with sudden death and cardiac transplantation[8].

Clinicopathological classification[9]

  • Acute myocarditis - Acute myocarditis presents with a less distinct onset of the illness. When the patient does present, there is already a decline in left ventricular dysfunction. Acute myocarditis may progress to dilated cardiomyopathy.
  • Chronic active myocarditis Chronic active myocarditis has a less distinct onset of the illness. There are clinical and histologic relapses and the development of ventricular dysfunction. Histologically, chronic inflammatory changes with mild to moderate fibrosis may be present.
  • Chronic persistent myocarditis - Chronic persistent myocarditis has a less distinct onset ff the illness. Histologically it is characterized by persistent infiltration and myocyte necrosis. Despite the presence of symptoms, ventricular dysfunction is absent.

Symptoms

The symptoms and the intensity of symptoms associated with myocarditis are variable. Myocarditis may be associated with no symptoms. If symptoms are present,they may be similar to the flu. Patients may present with chest pain as a result of the inflammatory process involving the myocardium or with symptoms of congestive heart failure. Patients may complain of palpitations, a racing heart or syncope. In fulminant myocarditis, patients present with the abrupt onset of flu-like symptoms and the abrupt onset of heart failure symptoms. In chronic and acute myocarditis, the onset of symptoms may be more insidious. Symptoms may include:

Diagnosis

Physical examination

Physical examination in patients with myocarditis may reveal tachycardia, a cardiac gallop, mitral regurgitation and pulmonary edema suggestive of cardiac failure. A pericardial friction rub may be noted in presence of concomitant pericarditis, a condition sometimes referred to as myopericarditis.

Electrocardiographic Findings

Common ECG findings in myocarditis include[11]:

ST segment elevation may also be seen in pericarditis. PR depression is also present, however, in patients with pericarditis.

Echocardiography

Echocardiography in patients with myocarditis allows for serial assessment of left ventricular dysfunction[10], and can be used to distinguish fulminant (non-dilated hypocontractile left ventricle with thick interventricular septum) from acute myocarditis (dilated hypocontractile left ventricle with normal interventricular septum)[10].

Echocardiographic findings in myocardits include:

In general, left ventricular function improves in fulminant myocarditis over a course of approximately 6 months[10].

Endomyocardial Biopsy

Endomyocardial biopsy remains the gold standard test to evaluate for the presence of and to subclassify the type of myocarditis. A small tissue sample of the endocardium and myocardium is obtained via right sided cardiac catheterization. The sample is then evaluated by a pathologist and if necessary using immunochemistry and special staining techniques. Histopathological features include abundant edema in the myocardial interstitium and an inflammatory infiltrate which is rich in lymphocytes and macrophages. Focal destruction of myocytes as a result of the inflammatory process explains the myocardial pump failure.[11]

Coronary Angiography

Coronary angiography may be helpful in excluding either myocardial ischemia or infarction as the cause of ST segment elevation, elevated cardiac biomarkers, or left ventricular dysfunction.

Cardiac Magnetic Resonance Imaging

Myocardial inflammation associated with myocarditis appears as a high intensity signal with delayed gadolinium hyperenhancement on cardiac MRI (cMRI). [16]. While the cMRI pattern of gadolinium hyperenhancement in ST segment elevation myocardial infarction is transmural and extends from the endocardium to the epicardium, the patchy, non-segmental hyperenhancement pattern in myocarditis in contrast involves the epicardium and spares the subendocardium[17].

Laboratory Findings

Myocardial inflammation can be suspected on the basis of the clinical history along with elevations of[11]:

Differentiating Myocarditis from Pericarditis and Myocardial Infarction

Myocarditis presents with chest pain and ST segment elevation. Myocarditis must be distinguished from pericarditis and the life threatening condition of ST elevation myocardial infarction.

Differentiating Myocarditis from ST Segment Elevation Myocardial Infarction

Both diseases present with chest pain, elevated cardiac biomarkers, and focal left ventricular dysfunction. There are two studies that can be used to distinguish the two syndromes:

Coronary Angiography

Coronary angiography can be performed to distinguish myocarditis from ST segment elevation myocardial infarction. ST segment elevation myocardial infarction is associated with either complete or subtotal occlusion of an epicardial coronary artery on coronary angiography.

Cardiac Magnetic Resonance Imaging

Cardiac magnetic resonance imaging is also useful in distinguishing between the two syndromes as well. On cardiac MRI, myocarditis is associated with patchy, non-sentimental, hyperenhancement which is confined to the epicardial layer of the myocardium. In contrast, in ST segment elevation myocardial infarction there is confluent hyperenhancement extending from the endocardium in a distribution that mimics the distribution of the epicardial coronary arteries.

Differentiating Myocarditis from Pericarditis

Both diseases present with chest pain and ST segment elevation. The two conditions can be distinguished by the following studies:

Electrocardiogram

While both disorders are associated with ST segment elevation, pericarditis is also associated with PR segment depression.

Cardiac Biomarkers

Myocarditis is associated with elevations of the CK-MB and the troponin, while pericarditis is not. If pericarditis is associated with underlying inflammation of the myocardium, then this is called myopericarditis. If there is concomitant involvement of both the pericardium and myocardium in myopericarditis, then there are elevations of the cardiac biomarkers.

Echocardiography

In patients with myocarditis there will be a focal wall motion abnormalities, while these will be absent in the patient with pericarditis. There may be a pericardial effusion in the patient with pericarditis, while myocarditis is not associated with a pericardial effusion.

Treatment

Insofar as most viral infections cannot be treated with directed therapy, symptomatic treatment is the mainstay of therapy for patients with viral myocarditis. Supportive therapy includes diuretics and inotropes for left ventricular failure. ACE inhibitor therapy may aid in left ventricular remodeling after the inflammation has begun to resolve. in patients with fulminant myocarditis, placement of an intra-aortic balloon pump or a left ventricular assist device may be necessary as bridge to recovery.

According to 2010 HFSA guidelines[18], routine use of immunosuppressive therapies in management of myocarditis is not recommended (Strength of Evidence A). Immunotherapy is beneficial in giant cell myocarditis. Finally, cardiac transplantation can be performed in patients with severe myocarditis who fail to recover.

Bacterial infections are treated with antibiotics the selection of which is based upon the nature of the pathogen and its sensitivity to antibiotics.

References

  1. Liu PP, Mason JW (2001). "Advances in the understanding of myocarditis". Circulation. 104 (9): 1076–82. PMID 11524405.
  2. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S (1998). "Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling". Circulation. 98 (2): 149–56. PMID 9679721.
  3. Lee JK, Zaidi SH, Liu P, Dawood F, Cheah AY, Wen WH; et al. (1998). "A serine elastase inhibitor reduces inflammation and fibrosis and preserves cardiac function after experimentally-induced murine myocarditis". Nat Med. 4 (12): 1383–91. doi:10.1038/3973. PMID 9846575.
  4. Badorff C, Lee GH, Lamphear BJ, Martone ME, Campbell KP, Rhoads RE; et al. (1999). "Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy". Nat Med. 5 (3): 320–6. doi:10.1038/6543. PMID 10086389.
  5. Ginsberg F, Parrillo JE (2005). "Eosinophilic myocarditis". Heart Fail Clin. 1 (3): 419–29. doi:10.1016/j.hfc.2005.06.013. PMID 17386864.
  6. Amini R, Nielsen C (2010). "Eosinophilic myocarditis mimicking acute coronary syndrome secondary to idiopathic hypereosinophilic syndrome: a case report". J Med Case Reports. 4: 40. doi:10.1186/1752-1947-4-40. PMC 2830978. PMID 20181108.
  7. 7.0 7.1 McCarthy RE, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Hare JM; et al. (2000). "Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis". N Engl J Med. 342 (10): 690–5. doi:10.1056/NEJM200003093421003. PMID 10706898.
  8. Scartazzini R, Schneider P, Bickel H (1975). "[New beta-lactam antibiotics. Functionalisation of the cephem 3-position with sulfur or nitrogen bearing substituents (author's transl)]". Helv Chim Acta. 58 (8): 2437–50. doi:10.1002/hlca.19750580824. PMID 1194054.
  9. Lieberman EB, Hutchins GM, Herskowitz A, Rose NR, Baughman KL (1991). "Clinicopathologic description of myocarditis". J Am Coll Cardiol. 18 (7): 1617–26. PMID 1960305.
  10. 10.0 10.1 10.2 10.3 Felker GM, Boehmer JP, Hruban RH, Hutchins GM, Kasper EK, Baughman KL; et al. (2000). "Echocardiographic findings in fulminant and acute myocarditis". J Am Coll Cardiol. 36 (1): 227–32. PMID 10898439.
  11. 11.0 11.1 11.2 Feldman AM, McNamara D (2000). "Myocarditis". N Engl J Med. 343 (19): 1388–98. doi:10.1056/NEJM200011093431908. PMID 11070105.
  12. 12.0 12.1 Pinamonti B, Alberti E, Cigalotto A, Dreas L, Salvi A, Silvestri F; et al. (1988). "Echocardiographic findings in myocarditis". Am J Cardiol. 62 (4): 285–91. PMID 3400607.
  13. Nieminen MS, Heikkilä J, Karjalainen J (1984). "Echocardiography in acute infectious myocarditis: relation to clinical and electrocardiographic findings". Am J Cardiol. 53 (9): 1331–7. PMID 6711435.
  14. James KB, Lee K, Thomas JD, Hobbs RE, Rincon G, Bott-Silverman C; et al. (1994). "Left ventricular diastolic dysfunction in lymphocytic myocarditis as assessed by Doppler echocardiography". Am J Cardiol. 73 (4): 282–5. PMID 8296760.
  15. Lieback E, Hardouin I, Meyer R, Bellach J, Hetzer R (1996). "Clinical value of echocardiographic tissue characterization in the diagnosis of myocarditis". Eur Heart J. 17 (1): 135–42. PMID 8682119.
  16. Abdel-Aty H, Boyé P, Zagrosek A, Wassmuth R, Kumar A, Messroghli D; et al. (2005). "Diagnostic performance of cardiovascular magnetic resonance in patients with suspected acute myocarditis: comparison of different approaches". J Am Coll Cardiol. 45 (11): 1815–22. doi:10.1016/j.jacc.2004.11.069. PMID 15936612.
  17. Skouri HN, Dec GW, Friedrich MG, Cooper LT (2006). "Noninvasive imaging in myocarditis". J. Am. Coll. Cardiol. 48 (10): 2085–93. doi:10.1016/j.jacc.2006.08.017. PMID 17112998.
  18. Heart Failure Society of America. Lindenfeld J, Albert NM, Boehmer JP, Collins SP, Ezekowitz JA; et al. (2010). "HFSA 2010 Comprehensive Heart Failure Practice Guideline". J Card Fail. 16 (6): e1–194. doi:10.1016/j.cardfail.2010.04.004. PMID 20610207.

Template:WH

Template:WS